EcoDrugPlus

Epidermal Growth Factor Receptor

Ensembl ID : ENSLCRG00005008076
Gene Symbol: EGFR
3 Cross references
215 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSLCRG00005012869
Gene Symbol: EGFRA
3 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2, Cytoplasmic

Ensembl ID : ENSLCRG00005005225
Gene Symbol: EPHX2
2 Cross references
203 Possible Orthologues:

Equilibrative Nucleoside Transporter 1

Ensembl ID : ENSLCRG00005004590
Gene Symbol: LOC104931166
3 Cross references
209 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSLCRG00005001141
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSLCRG00005005059
Gene Symbol: ERBB3
3 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3b

Ensembl ID : ENSLCRG00005012550
Gene Symbol: ERBB3B
3 Cross references
206 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSLCRG00005004324
Gene Symbol: ERBB4
3 Cross references
228 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSLCRG00005017119
Gene Symbol: ERBB4
3 Cross references
47 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSLCRG00005008511
Gene Symbol: ESR1
2 Cross references
215 Possible Orthologues:

Estrogen Receptor 2a

Ensembl ID : ENSLCRG00005021315
Gene Symbol: ESR2A
3 Cross references
198 Possible Orthologues:

Estrogen Receptor 2b

Ensembl ID : ENSLCRG00005014772
Gene Symbol: ESR2B
2 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).